Cargando…
Pharmacologic profiling reveals lapatinib as a novel antiviral against SARS-CoV-2 in vitro
The emergence of SARS-CoV-2 virus has resulted in a worldwide pandemic, but effective antiviral therapies are not widely available. To improve treatment options, we conducted a high-throughput screen to uncover compounds that block SARS-CoV-2 infection. A minimally pathogenic human betacoronavirus (...
Autores principales: | Raymonda, M.H., Ciesla, J.H., Monaghan, M., Leach, J., Asantewaa, G., Smorodintsev-Schiller, L.A., Lutz, M.M., Schafer, X.L., Takimoto, T., Dewhurst, S., Munger, J., Harris, I.S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8626825/ https://www.ncbi.nlm.nih.gov/pubmed/34871905 http://dx.doi.org/10.1016/j.virol.2021.11.008 |
Ejemplares similares
-
Cytomegalovirus-induced inactivation of TSC2 disrupts the coupling of fatty acid biosynthesis to glucose availability resulting in a vulnerability to glucose limitation
por: Raymonda, Matthew H., et al.
Publicado: (2023) -
Phase I and pharmacological trial of lapatinib in combination with gemcitabine in patients with advanced breast cancer
por: van der Noll, R., et al.
Publicado: (2015) -
BCAR4 induces antioestrogen resistance but sensitises breast cancer to lapatinib
por: Godinho, M F E, et al.
Publicado: (2012) -
Daily or weekly dosing with EGFR inhibitors, gefitinib and lapatinib, and AKT inhibitor MK2206 in mammary cancer models
por: Lubet, Ronald A., et al.
Publicado: (2018) -
Daily or weekly dosing with EGFR inhibitors, gefitinib and lapatinib, and AKT inhibitor MK2206 in mammary cancer models
por: Lubet, Ronald A., et al.
Publicado: (2019)